Morales AJ

No ORCID on file · 11 papers in corpus · active 1994-1999

Study types

  • article 5
  • other 3
  • case-report 1
  • review 1

Condition tags

  • endometriosis 10
  • chronic_pelvic_pain 2
  • infertility 1
other 1999
Fertility and Sterility ·doi:10.1016/s0015-0282(99)00145-4

OBJECTIVE: To measure autoantibodies that recognize oxidatively modified proteins in the sera of women with surgically proven endometriosis. DESIGN: Prospective study. SETTING: Tertiary care academic medical center. PATIENT(S): Women und…

other 1999
Obstetrics and gynecology clinics of North America ·doi:10.1016/s0889-8545(05)70062-0

Endometriosis is best regarded as a chronic disease that can vary in symptomatology over time. Endoscopic therapy for relief of pelvic pain as well as infertility is a therapeutic option. The formation of a rational treatment plan before su…

article 1998
Fertility and Sterility ·doi:10.1016/s0015-0282(98)00087-9

ObjectiveTo evaluate for the presence of oxidatively modified lipid-protein complexes in endometriosis and endometrium of women with endometriosis and controls.DesignControlled clinical study.SettingAcademic tertiary care center.Patient(s)W…

article 1998
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jcem.83.6.4823

Inflammatory processes have been hypothesized to mediate some of the clinical sequelae associated with endometriosis. The peritoneal fluid (PF) of women with endometriosis is known to contain more inflammatory cells and their associated cyt…

article 1998
Fertility and Sterility ·doi:10.1016/s0015-0282(98)00088-0

ObjectiveTo determine whether cultured human peritoneal macrophages have functional scavenger receptor(s) and whether activation of macrophages in endometriosis may involve an increase in scavenger receptor activity.DesignA controlled clini…

case-report 1998
American Journal of Obstetrics and Gynecology ·doi:10.1016/s0002-9378(98)70316-3

OBJECTIVE: We have previously shown that treatment with mifepristone, 50 to 100 mg daily, results in amenorrhea, anovulation, and symptomatic improvement in women with endometriosis. In this study we lowered the dose to 5 mg daily to determ…

review 1996
Clinical obstetrics and gynecology ·doi:10.1097/00003081-199606000-00018

RU-486, the first clinically available antiprogestin, has numerous gynecologic applications beyond first-trimester pregnancy termination. Long-term administration of 2 mg/day of RU-486 suppresses ovulation while maintaining serum estrogen l…

other 1996
Fertility and Sterility ·doi:10.1016/s0015-0282(16)58022-4

OBJECTIVE: To evaluate the safety and efficacy of an antiprogesterone (mifepristone, RU486; Roussel-Uclaf, Romaineville, France) on endometriosis. DESIGN: An open, prospective clinical trial. SETTING: The clinical practice of an academic …

article 1995
Fertility and Sterility ·doi:10.1016/s0015-0282(16)57478-0

ObjectiveTo examine endometrial response to long-term low-does RU486 administration.DesignRetrospective controlled study of women with endometriosis treated for 6 months with 50 mg RU486 daily for 6 months. Controls consisted of women in th…

1994
The Journal of clinical investigation ·doi:10.1172/jci117551

RU-486 (17 beta-hydroxy-4-dimethylaminophenyl-17-alpha-propenyl estrone 4,9 diene-3-one; mifepristone) is suggested to act by binding to progesterone and glucocorticoid receptors. Based on its chemical nature, we anticipated that RU-486 may…

article 1994
Human Reproduction ·doi:10.1093/humrep/9.suppl_1.116

To evaluate the long-term effects of treatment with RU486 and to test its efficacy in endometriosis, a 3-month trial was conducted to evaluate the effects of daily administration (100 mg/day or approximately 2 mg/kg/day) on the functional a…